Ligand earns milestone from SAGE Therapeutics for SAGE-547 Ligand Pharmaceuticals announced that it has earned a $150,000 milestone payment from SAGE Therapeutics relating to the earlier commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus, a life-threatening seizure condition in which the brain is in a state of persistent seizure. SAGE-547 is an intravenous agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE. SAGE utilizes Ligandís Captisol technology to develop SAGE-547 for status epilepticus and traumatic brain injury. In 2013, Ligand entered into a platform license agreement with SAGE for the development and commercialization of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions. Elements of that agreement were also recently expanded to cover additional therapy areas for certain compounds.